- Home
- CIEN vs ROIV Comparison
CIEN vs ROIV Comparison
Compare CIEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIEN
- ROIV
- Stock Information
- Founded
- CIEN 1992
- ROIV 2014
- Country
- CIEN United States
- ROIV United Kingdom
- Employees
- CIEN N/A
- ROIV N/A
- Industry
- CIEN Telecommunications Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CIEN Utilities
- ROIV Health Care
- Exchange
- CIEN Nasdaq
- ROIV Nasdaq
- Market Cap
- CIEN 8.4B
- ROIV 8.4B
- IPO Year
- CIEN 1997
- ROIV N/A
- Fundamental
- Price
- CIEN $81.22
- ROIV $10.79
- Analyst Decision
- CIEN Buy
- ROIV Buy
- Analyst Count
- CIEN 13
- ROIV 4
- Target Price
- CIEN $78.62
- ROIV $17.50
- AVG Volume (30 Days)
- CIEN 1.5M
- ROIV 5.9M
- Earning Date
- CIEN 06-05-2025
- ROIV 05-29-2025
- Dividend Yield
- CIEN N/A
- ROIV N/A
- EPS Growth
- CIEN N/A
- ROIV N/A
- EPS
- CIEN 0.55
- ROIV N/A
- Revenue
- CIEN $4,049,506,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CIEN $12.65
- ROIV N/A
- Revenue Next Year
- CIEN $8.89
- ROIV N/A
- P/E Ratio
- CIEN $147.80
- ROIV N/A
- Revenue Growth
- CIEN N/A
- ROIV 140.04
- 52 Week Low
- CIEN $44.69
- ROIV $8.73
- 52 Week High
- CIEN $101.44
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CIEN 74.40
- ROIV 50.06
- Support Level
- CIEN $78.46
- ROIV $10.58
- Resistance Level
- CIEN $81.48
- ROIV $11.77
- Average True Range (ATR)
- CIEN 2.30
- ROIV 0.34
- MACD
- CIEN 1.15
- ROIV -0.07
- Stochastic Oscillator
- CIEN 98.45
- ROIV 17.65
About CIEN Ciena Corporation
Ciena Corp is a network and technology company. It provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks. It serves various industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises world-wide. The business activities function through Networking Platforms which generates maximum revenue; Platform Software and Services; Blue Planet Automation Software, and Global Services segments. Geographically, the company derives a majority of its revenue from the Americas, and the rest from the Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA) region.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.